Arbitrum has proposed a constitutional-level governance change to allow new Stylus contract activations on Arbitrum One, following a halt on Oct. 2 due to security concerns. The proposal requires each new contract to undergo a limited security audit by an approved auditor and receive approval from the Arbitrum Foundation multisig before activation. Existing active contracts can continue and renew without permission, while ArbitrumDAO retains the power to revoke or alter the Foundation's authorization through governance votes. This move aims to balance security with developer flexibility in building WebAssembly programs on Arbitrum.
Arbitrum's governance proposal to resume Stylus contract activations follows a security review process. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Oct 24, 2026 20:01 WIB: out of 50 major cryptocurrencies, 5 rose and 43 fell. Notable movers include UNI at Rp123.403 with a 1-day change of -4.84% and a Pluang order activity of 52% Sell / 48% Buy, AXS at Rp17.405 with a 1-day change of -4.58% and 0% Sell / 100% Buy order activity, and GRT at Rp415 with a 1-day change of -4.46% and 28% Sell / 72% Buy order activity.
The Royal Canadian Legion has launched its 2026 National Poppy Campaign introducing a new contactless donation method using smartphones, supported by BMO and Toucan Giving technology. This innovation allows volunteers to collect donations via debit, ...
XBiotech Inc. announced the election of Jan-Paul Simard as Co-Chief Executive Officer alongside current CEO Dr. Sushma Shivaswamy, effective October 23, 2026. This leadership change aims to leverage their complementary skills and scientific expertise...
XBiotech Inc. announced the appointment of Sushma Shivaswamy and Jan-Paul Simard as co-chief executive officers, effective October 23, 2026. Shivaswamy, with 17 years at the company, has led scientific operations and was interim CEO since December 20...
Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...
Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...
